Moderna’s melanoma result arrives before the Phase 3 dataset
Moderna reported a positive Phase 3 result for a personalized mRNA melanoma therapy, producing both hope and a familiar demand from HN: show the underlying data.
The announcement concerns an mRNA neoantigen therapy developed with Merck; commenters welcomed the prospect while noting that company statements are not the same as a published dataset.
The tension is healthy rather than cynical: oncology trials fail often, and a clinical headline needs endpoints, duration, and safety detail before it becomes practice.
A positive result is not the full readout
The reported Phase 3 result concerns Moderna and Merck’s personalized mRNA neoantigen therapy with Keytruda in melanoma. It is potentially consequential because recurrence prevention is a hard clinical target.
The thread asked for endpoints and follow-up
HN readers did not reject the result; they asked for the data that determines its meaning. A press release can establish that a trial met a stated endpoint, but clinicians and patients need the magnitude of benefit, safety profile, duration of follow-up, and the population studied.
Hope should keep its denominator
The better way to hold the news is neither dismissal nor triumphalism. Treat the result as a reason to read the eventual detailed evidence, especially where a treatment’s benefit must be weighed against toxicity and cost.
Get breakdowns like this every day
The top Hacker News stories, unpacked — by email, Telegram, or RSS.
Casio adds Bluetooth without turning the F-91W into a smartwatch
Casio’s F-B100W-1A keeps the familiar digital-watch premise while adding Bluetooth syncing and a step counter with an advertised two-year battery life.